About BESUNYEN Company

Bishengyuan Holdings Limited (the “Company”) was established in September 2000 and listed on the main board of the Hong Kong Stock Exchange in September 2010 (stock code HK00926). Bishengyuan Holdings Co., Ltd. and its subsidiaries (collectively, the “Group”) are leading suppliers of functional health teas in the People's Republic of China (“China”), mainly engaged in research and development, production of health products, and sales and promotion of pharmaceuticals and foods. The Group uses “one vertical and two horizontal” as its guideline: one vertical means focusing on herbal plants and health; two horizontal means expanding new businesses in the fields of “weight loss and weight management” and “bowel cleansing and gastrointestinal health.” For more than 20 years, the Group has produced and sold Bishengyuan brand Changrun tea and Bishengyuan brand Changjing tea (formerly “Bishengyuan brand weight loss tea”) (collectively known as “two teas”) based on the concept of “herbal, healthy, and functional tea”. The Group continues to be deeply involved in the two tea business and has successively launched a series of functional tea products such as Bishengyuan brand fiber tea and Bishengyuan brand Qingyuan tea (collectively known as “four teas” with two teas). In recent years, the Group has also launched Bishengyuan brand orlistat diet drugs and a series of products to meet consumer needs, such as nutritional meal replacements, probiotics, and enzymes. All four teas in the Group are developed, prepared, and produced according to scientific standards using natural Chinese herbal medicines and tea leaves to provide safe, effective, easy to use, and affordable health care products for people with needs for bowel relief and weight management, or whose health and quality of life are moderately affected by them. The Group's four tea production base is located in Fangshan District, Beijing. The plant and production process meet national GMP standards. The production workshop is fully managed, and the granulation workshop and inner packaging workshop are all 100,000-grade clean areas. The Group's four tea products have all passed ISO9001, ISO22000, and HACCP system certifications. The main production equipment is the C24 high-speed tea bag model introduced from IMA in Italy. It has a specially designed “cotton crew knot” to connect the tea bag to the tag. The inner and outer bags are formed once, and the entire packaging process is automatically completed. The Group's “Bishengyuan and Tu” trademark was recognized as a “China Famous Trademark” by the Trademark Office of the former China State Administration for Industry and Commerce in 2013. The Bishengyuan brand has been rated by the China Health Association as one of the top ten credible brands of health products in China for five consecutive years. The Group has successively obtained the “High-tech Enterprise Certificate” issued by the Beijing Municipal Science and Technology Commission, the “Beijing Leading Enterprise” title issued by the Beijing Municipal Bureau of Agriculture and Rural Affairs, the “Beijing “Innovative” SME and the “Special and New” SME titles issued by the Beijing Municipal Bureau of Economy and Information Technology. The Group has 26 health food approvals issued by the China Food and Drug Administration and 114 patented technologies issued by the State Intellectual Property Office, including 20 invention patents. In the first half of 2024, the Group's offline sales business covered nearly 290,000 over-the-counter (“OTC”) pharmacies and pharmaceutical terminals in 31 provinces, autonomous regions and municipalities across the country through new business partners. The Group's online e-commerce business has set up 63 stores on 18 e-commerce platforms to sell four tea, orlistat and other Group products. The Group actively embraces the development of the new sales situation and continues to experiment with new retail areas such as Douyin, Kuaishou, O2O, and B2C. Through these mature and innovative channels, the Group's new products can enter the market more quickly, so that the Group's product sales can continue to maintain its leading position in the industry. The Group will continue to adhere to market-oriented, technology-driven, quality as life, continuous innovation, strive to provide consumers with more high-quality health products and services, and become a leader in the health industry.